BackBetter Therapeutics- Tradeable Rights - March 2021 Overview

Better Therapeutics- Tradeable Rights - March 2021 Intangible Assets

Track Better Therapeutics- Tradeable Rights - March 2021's intangible assets ($2.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$2.79M
32.25% YoYΔ $-1.33M vs prior year quarter

Peer average

Loading

Better Therapeutics- Tradeable Rights - March 2021 Intangible Assets History

Loading

Better Therapeutics- Tradeable Rights - March 2021 vs. peers: Intangible Assets Comparison

Loading

Better Therapeutics- Tradeable Rights - March 2021 Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Better Therapeutics- Tradeable Rights - March 2021 (MCADR) FAQ

Better Therapeutics- Tradeable Rights - March 2021 posts a intangible assets of $2.8M as of September 2023. That compares with $4.1M in the prior-year period — down 32.2% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Better Therapeutics- Tradeable Rights - March 2021's intangible assets was $4.1M. The latest reading is $2.8M — a 32.2% year-over-year decrease (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

Intangible Assets is one piece of Better Therapeutics- Tradeable Rights - March 2021's financial statement story. At $2.8M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for MCADR's intangible assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Better Therapeutics- Tradeable Rights - March 2021's other metric pages and overview cover the third.